STAT Plus: Pharmalittle: Gilead to pay $21 billion to buy Immunomedics; Trump releases executive order on drug pricing

Gilead Sciences will pay $21 billion to buy Immunomedics and its prized breast-cancer drug, culminating a move into oncology that investors have been expecting.

Click to view original post